form8k122809.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported) December 24, 2009
NOVADEL
PHARMA INC.
(Exact
Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-32177
|
|
22-2407152
|
(State
or other jurisdiction
of
incorporation or organization)
|
|
(Commission
File No.)
|
|
(I.R.S.
Employer
Identification
No.)
|
25
Minneakoning Road
Flemington,
New Jersey 08822
(Address
of principal executive offices) (Zip Code)
(908)
782-3431
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other
Events.
On
December 24, 2009, NovaDel Pharma Inc. (the “Company”) issued a press release
announcing that its common stock would begin trading on the Over-the-Counter
Bulletin Board (“OTCBB”) on December 24, 2009 under the trading symbol “[NVDL]”.
The final day of trading on NYSE Amex, LLC (“Amex”) was December 23,
2009.
As
previously disclosed on a Current Report on Form 8-K filed on December 3, 2009,
the Company had announced its intention to voluntarily delist its common stock
from Amex and to file a Form 25 with the Securities and Exchange Commission on
December 14, 2009. As previously disclosed, the Board of Directors of
the Company had approved the voluntary delisting of the Company’s common stock
from Amex and the transfer of the listing to the OTCBB on October 15, 2009,
subject to the Company’s review of certain events, which was subsequently
ratified on December 2, 2009.
The press
release announcing the Company’s transfer of listing is attached as Exhibit
99.1.
Item
9.01. Financial
Statements and Exhibits.
(d)
Exhibits.
99.1
|
Press
release of NovaDel Pharma Inc., dated December 24, 2009, titled “NovaDel
Announces Listing on OTC Bulletin
Board.”
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NovaDel Pharma Inc. |
|
|
By:
|
/s/
Steven B. Ratoff
|
Name:
|
Steven
B. Ratoff
|
Title:
|
Chairman,
Interim Chief Financial Officer, Interim President and Chief Executive
Officer
|
Date: December
28, 2009